Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

DANMARKS STØRSTE INVESTORSITE MED DEBAT, CHAT OG NYHEDER
Q&A med Genmab A/S, 26 August Kl. 16:30 Læs mere her
      

Tror folk på en opjustering fra AMBU ?


84877 DSDK 30/6 2020 13:19
Oversigt

Kunne der være en snarlig opjustering på trapperne fra AMBU forud for Q3?



30/6 2020 19:56 tommycarstensen 084886



DSDK Forventes en opjustering?

https://www.ambu.com/corporate-info/investors/news-fr..
The sales outlook for the full year was upgraded on 6 April 2020 due to the higher-than-expected growth in Q2. The outlook for organic revenue growth was increased from "16-22%" to "26-30%", and the guidance on the number of endoscopes sold was increased from "approx. 900,000" to "more than 1 million".
The outlook for the EBIT margin before special items was suspended on 6 April 2020 and is now resumed at 12-14%. This interval reflects our decision to accelerate our commercial infrastructure expansion into GI and urology and ensure the successful launches of aScope™ Duodeno and aScope™ 4 Cysto.
The outlook for the financial year 2019/20 is:
Organic growth in the range of 26-30%.
EBIT margin before special items in the range of 12-14%.
Sales of more than 1 million endoscope units.

AMBU




TRÅDOVERSIGT